315 related articles for article (PubMed ID: 10443322)
1. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes.
Wiernsperger NF
Diabetes Metab; 1999 Jun; 25(2):110-27. PubMed ID: 10443322
[TBL] [Abstract][Full Text] [Related]
2. Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.
Yoshida T; Okuno A; Tanaka J; Takahashi K; Nakashima R; Kanda S; Ogawa J; Hagisawa Y; Fujiwara T
Eur J Pharmacol; 2009 Nov; 623(1-3):141-7. PubMed ID: 19765581
[TBL] [Abstract][Full Text] [Related]
3. Evidence that metformin ameliorates cellular insulin-resistance by potentiating insulin-induced translocation of glucose transporters to the plasma membrane.
Matthaei S; Greten H
Diabete Metab; 1991 May; 17(1 Pt 2):150-8. PubMed ID: 1718789
[TBL] [Abstract][Full Text] [Related]
4. Regulation of glucose-6-phosphatase gene expression by insulin and metformin.
Mues C; Zhou J; Manolopoulos KN; Korsten P; Schmoll D; Klotz LO; Bornstein SR; Klein HH; Barthel A
Horm Metab Res; 2009 Oct; 41(10):730-5. PubMed ID: 19579180
[TBL] [Abstract][Full Text] [Related]
5. A proposal for the locus of metformin's clinical action: potentiation of the activation of pyruvate kinase by fructose-1,6-diphosphate.
McCarty MF
Med Hypotheses; 1999 Feb; 52(2):89-93. PubMed ID: 10340287
[TBL] [Abstract][Full Text] [Related]
6. Effect of metformin on insulin-stimulated tyrosine kinase activity of erythrocytes from obese women with normal glucose tolerance.
Santos RF; Nomizo R; Bopsco A; Wajchenberg BL; Reaven GM; Azhar S
Diabetes Metab; 1997 Apr; 23(2):143-8. PubMed ID: 9137903
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
[TBL] [Abstract][Full Text] [Related]
8. Improvement of insulin action is an important part of the antidiabetic effect of metformin.
Schernthaner G
Horm Metab Res Suppl; 1985; 15():116-20. PubMed ID: 3908277
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
10. Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Arulmozhi DK; Kurian R; Bodhankar SL; Veeranjaneyulu A
J Pharm Pharmacol; 2008 Sep; 60(9):1167-73. PubMed ID: 18718120
[TBL] [Abstract][Full Text] [Related]
11. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
12. The potential biological mechanisms of arsenic-induced diabetes mellitus.
Tseng CH
Toxicol Appl Pharmacol; 2004 Jun; 197(2):67-83. PubMed ID: 15163543
[TBL] [Abstract][Full Text] [Related]
13. Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model.
Koopmans SJ; Mroz Z; Dekker R; Corbijn H; Ackermans M; Sauerwein H
Metabolism; 2006 Jul; 55(7):960-71. PubMed ID: 16784971
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
Strowig SM; Raskin P
Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007
[TBL] [Abstract][Full Text] [Related]
15. Metformin and pioglitazone: Effectively treating insulin resistance.
Staels B
Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
[TBL] [Abstract][Full Text] [Related]
16. The antidiabetic effects of cysteinyl metformin, a newly synthesized agent, in alloxan- and streptozocin-induced diabetic rats.
Liu Z; Li J; Zeng Z; Liu M; Wang M
Chem Biol Interact; 2008 May; 173(1):68-75. PubMed ID: 18377884
[TBL] [Abstract][Full Text] [Related]
17. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms.
Wiernsperger NF; Bailey CJ
Drugs; 1999; 58 Suppl 1():31-9; discussion 75-82. PubMed ID: 10576523
[TBL] [Abstract][Full Text] [Related]
18. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
[TBL] [Abstract][Full Text] [Related]
19. Current indications for metformin therapy.
Tankova T
Rom J Intern Med; 2003; 41(3):215-25. PubMed ID: 15526505
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of insulin action and tumor necrosis factor alpha system activity by metformin.
Biarnés J; Fernández-Real JM; Fernández-Castañer M; del Mar García M; Soler J; Ricart W
Metabolism; 2005 Feb; 54(2):235-9. PubMed ID: 15690319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
